Biopharma commercialization has become increasingly complex—yet the tools and processes many teams rely on haven’t kept pace. As strategies, data, funding, and teams evolve, maintaining alignment and a clear, shared view of the plan becomes harder, creating friction at the very moment when precision and speed matter most.
In this video, Sue Nemetz—founder and CEO of Corval—shares her perspective on the root causes behind these challenges and why a more modern, purpose-built approach to commercialization planning is needed. Drawing on decades of experience, she outlines how rethinking the way teams plan, collaborate, and adapt can unlock better decisions and ultimately improve outcomes for both organizations and patients.
If these challenges resonate, there’s a better way forward. Corval is purpose-built to bring clarity, alignment, and adaptability to biopharma commercialization planning. Explore how Corval can support your team in building stronger, more connected plans—and ultimately getting therapies to patients more effectively.
